Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ITOS |
---|---|---|
09:32 ET | 1152 | 20.33 |
09:33 ET | 300 | 20.8 |
09:37 ET | 570 | 20.54 |
09:42 ET | 100 | 20.56 |
09:46 ET | 100 | 20.675 |
09:50 ET | 200 | 20.72 |
09:53 ET | 400 | 20.85 |
09:55 ET | 100 | 20.85 |
09:57 ET | 1412 | 20.8 |
10:09 ET | 100 | 20.74 |
10:13 ET | 100 | 20.77 |
10:18 ET | 3278 | 20.825 |
10:20 ET | 4855 | 20.75 |
10:27 ET | 100 | 20.86 |
10:33 ET | 344 | 20.85 |
10:36 ET | 300 | 20.855 |
10:38 ET | 735 | 20.9214 |
10:42 ET | 200 | 20.855 |
10:45 ET | 200 | 20.89 |
10:47 ET | 100 | 20.94 |
10:49 ET | 100 | 20.89 |
10:51 ET | 100 | 20.955 |
10:54 ET | 100 | 20.83 |
11:00 ET | 100 | 20.875 |
11:02 ET | 100 | 20.93 |
11:07 ET | 2089 | 20.93 |
11:12 ET | 100 | 20.965 |
11:14 ET | 200 | 20.96 |
11:21 ET | 1308 | 20.94 |
11:23 ET | 300 | 21.01 |
11:27 ET | 700 | 20.9297 |
11:30 ET | 200 | 20.94 |
11:34 ET | 100 | 20.91 |
11:36 ET | 6500 | 20.85 |
11:38 ET | 100 | 21.015 |
11:41 ET | 500 | 20.95 |
11:43 ET | 200 | 20.965 |
11:45 ET | 100 | 20.83 |
11:48 ET | 100 | 20.965 |
11:54 ET | 100 | 20.84 |
11:57 ET | 1300 | 20.83 |
11:59 ET | 200 | 20.795 |
12:03 ET | 100 | 20.76 |
12:06 ET | 226 | 20.76 |
12:08 ET | 500 | 20.78 |
12:14 ET | 640 | 20.78 |
12:15 ET | 100 | 20.855 |
12:19 ET | 100 | 20.795 |
12:42 ET | 600 | 20.87 |
12:44 ET | 100 | 20.965 |
12:51 ET | 1000 | 20.845 |
12:53 ET | 500 | 20.76 |
12:57 ET | 200 | 20.76 |
01:06 ET | 100 | 20.815 |
01:08 ET | 1100 | 20.9 |
01:11 ET | 200 | 20.93 |
01:29 ET | 1342 | 20.98 |
01:38 ET | 100 | 21.03 |
01:40 ET | 200 | 20.94 |
01:42 ET | 214 | 20.97 |
01:44 ET | 700 | 20.95 |
01:47 ET | 1881 | 20.93 |
01:51 ET | 100 | 20.93 |
01:54 ET | 2330 | 20.89 |
01:56 ET | 200 | 20.93 |
01:58 ET | 250 | 20.8576 |
02:02 ET | 200 | 20.84 |
02:09 ET | 600 | 20.82 |
02:12 ET | 100 | 20.84 |
02:18 ET | 500 | 20.86 |
02:20 ET | 800 | 20.815 |
02:21 ET | 500 | 20.86 |
02:23 ET | 650 | 20.85 |
02:32 ET | 100 | 20.81 |
02:36 ET | 1300 | 20.78 |
02:41 ET | 1291 | 20.78 |
02:43 ET | 500 | 20.7301 |
02:52 ET | 500 | 20.82 |
02:54 ET | 100 | 20.86 |
03:01 ET | 100 | 20.9 |
03:03 ET | 900 | 20.79 |
03:10 ET | 100 | 20.73 |
03:12 ET | 100 | 20.76 |
03:14 ET | 100 | 20.795 |
03:17 ET | 300 | 20.74 |
03:19 ET | 300 | 20.72 |
03:21 ET | 410 | 20.69 |
03:32 ET | 100 | 20.71 |
03:33 ET | 100 | 20.71 |
03:37 ET | 700 | 20.69 |
03:39 ET | 200 | 20.66 |
03:44 ET | 100 | 20.65 |
03:46 ET | 1110 | 20.62 |
03:48 ET | 800 | 20.66 |
03:50 ET | 255 | 20.64 |
03:51 ET | 1788 | 20.8 |
03:53 ET | 300 | 20.81 |
03:55 ET | 717 | 20.81 |
03:57 ET | 2013 | 20.86 |
04:00 ET | 6073 | 20.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Iteos Therapeutics Inc | 725.4M | 3.1x | --- |
Intercept Pharmaceuticals Inc | 743.0M | -3.0x | --- |
Coherus BioSciences Inc | 633.1M | -2.4x | --- |
Agenus Inc | 722.1M | -3.3x | --- |
CareDx Inc | 784.3M | -10.7x | --- |
Atea Pharmaceuticals Inc | 384.0M | 12.9x | --- |
iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients with cancer. The Company's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant. The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its inupadenant, is an adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment. The Company is conducting an open-label multi-arm Phase I/IIa clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $725.4M |
---|---|
Revenue (TTM) | $454.2M |
Shares Outstanding | 35.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $6.80 |
Book Value | $15.59 |
P/E Ratio | 3.1x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | 2.8x |
Operating Margin | 70.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.